- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
British journal of haematology (2016-12-23)
Noopur S Raje, Philippe Moreau, Evangelos Terpos, Lotfi Benboubker, Norbert Grząśko, Sarah A Holstein, Albert Oriol, Shang-Yi Huang, Meral Beksac, Kazimierz Kuliczkowski, Datchen F Tai, James E Wooldridge, Ilaria Conti, Christopher J Kaiser, Tuan S Nguyen, Damien M Cronier, Antonio Palumbo
PMID28005265
摘要
In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N = 72), tabalumab 100 mg (N = 74), or tabalumab 300 mg (N = 74), each in combination with dexamethasone 20 mg and subcutaneous bortezomib 1·3 mg/m